Cocaine-Related Disorders Clinical Trial
Official title:
The Effects of GABA Medications on Cocaine Responses in Humans
Gamma-aminobutyric acid (GABA) is a type of neurotransmitter, which is a chemical that transmits information within and from the brain to all parts of the body. By lowering the level of another neurotransmitter called dopamine, GABA may have the ability to diminish cocaine cravings in addicts. The purpose of this study is to gather information on the interaction between cocaine and selected GABA enhancing medications in individuals addicted to cocaine. This may lead to future clinical studies using GABA medications to treat cocaine addiction.
GABA is an inhibitory neurotransmitter that is found primarily in the brain. High GABA
levels result in low levels of dopamine, another neurotransmitter that is the brain's "feel
good" chemical and which plays a primary role in cocaine drug addiction. Cravings for
cocaine can be reduced by lowering dopamine levels. This makes GABA-altering medications a
potential treatment for cocaine addiction. This study will involve five GABA enhancing
medications: tiagabine, topiramate, valproic acid, baclofen, and progesterone. The purpose
of the study is to evaluate the interaction between GABA medications and cocaine in terms of
safety and craving responses. In turn, these findings may guide future cocaine
pharmacotherapy trials.
This 6-day inpatient study will begin with an orientation session to familiarize
participants with study procedures. The evening of Day 1, all participants will receive
placebo medication. On Days 2 through 4, participants will receive one of five GABA
medications. The GABA medications will be given in gradually increasing doses to attain
therapeutic levels while maintaining safety and minimizing side effects. Three experimental
cocaine sessions will take place; one while the participants are receiving the placebo
medication and two while the participants are receiving the GABA medications. During these
sessions, cocaine will be administered intravenously in three increasing doses, each
separated by 30-minute intervals. This will allow the participants' subjective and
physiological responses during cocaine administration to return to baseline levels before
the next dose. Blood will be drawn after each dose; heart rate, blood pressure, and an ECG
will be monitored throughout the sessions. At the end of each session, questionnaires will
be administered to assess the effects of cocaine and related mood states, as well as allow
the participants to report any adverse events, depression, craving, or withdrawal symptoms.
This study is now closed and published.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01526538 -
Improving Learning-based Treatment of Cocaine Dependence With Medication
|
Phase 2 | |
Completed |
NCT00877435 -
Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial
|
N/A | |
Completed |
NCT00430690 -
Acoustic Startle Reduction In Cocaine Dependence
|
||
Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
Active, not recruiting |
NCT00094315 -
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
|
Phase 1 | |
Completed |
NCT00218348 -
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo
|
Phase 2 | |
Completed |
NCT00142844 -
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
|
Phase 2 | |
Completed |
NCT00158132 -
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00000294 -
Effects of Carvedilol on Cocaine Use in Humans - 11
|
Phase 2 | |
Completed |
NCT00015054 -
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3
|
Phase 2 | |
Completed |
NCT00000308 -
Dextroamphetamine-Cocaine Behavioral Intervention - 5
|
Phase 2 | |
Completed |
NCT00000314 -
M-CPP and Fenfluramine in Cocaine Addicts - 3
|
Phase 2 | |
Completed |
NCT00000188 -
Selegiline in Treatment of Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000281 -
Pharmacotherapy for Schizophrenic Drug Users - 6
|
Phase 2 | |
Completed |
NCT00000282 -
Pemoline for Cocaine Abuse - 7
|
Phase 2 | |
Terminated |
NCT00000276 -
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
|
Phase 1 | |
Completed |
NCT00000278 -
Disulfiram for Cocaine-Alcohol Abuse - 3
|
Phase 2 | |
Completed |
NCT00000277 -
Mazindol for Cocaine Abuse - 2
|
Phase 2 | |
Completed |
NCT00000280 -
Glutaminergic Agents for Cocaine Abuse - 5
|
Phase 1 |